IGC Pharma Inc (A:IGC)

Business Focus: Biotechnology & Medical Research

Apr 16, 2024 07:00 am ET

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo.

Apr 09, 2024 09:00 am ET

IGC Pharma Adds Advisor in Artificial Intelligence

IGC Pharma, Inc. ("IGC Pharma," "IGC" or the "Company") (NYSE American: IGC) today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world's top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC-AD1, IGC Pharma’s lead therapeutic candidate targeting agitation in Alzheimer’s disease. Recent interim results from the IGC-AD1 Phase 2 trial demonstrated a clinically and statistically significant reduction in agitation compared to placebo in patients with Alzheimer's disease, indicating strong therape

Mar 26, 2024 03:00 pm ET

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”), a leading asset management firm.

Mar 20, 2024 11:00 am ET

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced the results of an interim analysis of its ongoing Phase 2 trial investigating IGC-AD1 as a treatment for Agitation in dementia from Alzheimer’s Disease (“AAD”).

Mar 20, 2024 07:00 am ET

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

IGC Pharma, Inc. (“IGC Pharma”, “IGC”, or the “Company”) (NYSE American: IGC) today announced that Ram Mukunda, CEO, and Claudia Grimaldi, Vice President, will participate in a fire chat at the BENZINGA VIRTUAL HEALTHCARE SUMMIT 2024 (https://www.benzing

Mar 12, 2024 03:00 pm ET

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.

Feb 28, 2024 01:00 pm ET

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced the results of preclinical studies investigating its drug candidate TGR-63 as a treatment for Alzheimer's disease. The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Feb 23, 2024 12:01 pm ET

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the Company’s common stock.

Feb 16, 2024 07:05 pm ET

IGC Pharma Reports Third Quarter Fiscal 2024 Results

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).

Feb 01, 2024 09:20 am ET

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced additional positive results of preclinical studies investigating the Company's newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer's disease. Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer's cell lines and animal models. Plaques are a key hallmark and therapeutic target of Alzheimer's disease.

Jan 23, 2024 09:20 am ET

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) provides details on its drug candidate TGR-63, which targets amyloid-beta plaque and can potentially improve Alzheimer's disease treatment in a significant manner.

Jan 17, 2024 09:20 am ET

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that ClinCloud, a clinical research facility in Florida, has dosed its first patient as part of the Company’s ongoing Phase 2b trial.

Dec 19, 2023 09:20 am ET

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s

IGC Pharma, Inc. (“IGC Pharma” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, announced today that Divisional Direction of Patents, Mexico, has issued a Granting Office Action (GOA) for its treatment of Alzheimer’s disease titled “Method and Composition for Treating CNS Disorder.” The Company is optimistic that the success witnessed in Mexico can pave the way for additional approvals in the U.S. and Europe.

Dec 13, 2023 09:30 am ET

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced that the Company’s management team will participate in Biotech Showcase and BIO Partnering @ JPM, held in-person and scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2024.

Dec 06, 2023 08:30 am ET

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University’s Center for Research and Training in Artificial Intelligence (“CINFONIA”). The partnership aims to leverage Generative AI (AI) to analyze variations in disease signatures among patients, enabling IGC Pharma to identify individuals more likely to respond to treatment and subsequently accelerate the delivery of treatments to patients.

Nov 21, 2023 08:30 am ET

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

IGC Pharma, Inc. (“IGC Pharma,” "IGC" or the "Company") (NYSE American: IGC) today announced a Master Cooperation Agreement with the University of Los Andes for the development and adoption of generative AI solutions into the Company’s drug identification, development, and clinical trial processes. IGC Pharma will be focused on advancing various AI initiatives including:

Nov 13, 2023 08:00 am ET

IGC Pharma Reports Second Quarter Fiscal 2024 Results

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the second fiscal quarter of 2024 ended September 30, 2023 (Q2 FY2024).

Oct 19, 2023 03:30 pm ET

IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy

IGC Pharma, Inc. (“IGC,” “IGC Pharma” or the “Company”) (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, is thrilled to announce a significant milestone: the grant of European Patent No. 3193862 by the European Patent Office (“EPO”) for our innovative "Cannabinoid Composition and Method for Treating Pain."

Aug 21, 2023 02:30 pm ET

IGC Announces Results of its 2023 Annual Stockholders Meeting

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 18, 2023 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 26, 2023, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of June 21, 2023, were entitled to and requested to vote at the Annual Meeting.

Aug 14, 2023 08:30 am ET

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended June 30, 2023, which is the first quarter of the Company’s 2024 fiscal year.

Aug 02, 2023 08:30 am ET

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

IGC Pharma, Inc (NYSE American: IGC) (“IGC” or the “Company”), today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of the Company’s ongoing Phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease.

Jul 18, 2023 05:22 am ET

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company, today announced that it is presenting 6 in-person posters highlighting data from its Phase 1 clinical trials investigating the Company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”) being held July 16-20, 2023, in Amsterdam, Netherlands.

Jul 12, 2023 08:44 am ET

IGC Reports Financial Results for Fiscal Year Ended March 31, 2023

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”).

Jul 07, 2023 09:15 am ET

IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co., Ltd. (“O-Bank” or the “Bank”). This funding will support IGC’s working capital needs primarily related to its Alzheimer’s research.

Jul 06, 2023 07:46 am ET

IGC Pharma Announces a $3 Million Private Placement of its Common Stock

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced a strategic investment from four investment funds managed by Bradbury Asset Management (Hong Kong) Limited (“Bradbury”) who is a leading asset management firm with over $2 billion in managed assets. This investment, along with additional contributions from three unrelated investors, has resulted in approximately $3 million in gross proceeds, further strengthening IGC’s working capital. The funds support the advancement of the Company’s Phase-2 clinical trial of IGC-AD1, the Company’s promising investigational drug c

Jun 06, 2023 09:20 am ET

IGC Pharma Receives Notice of Allowance for Patent on Seizures

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that it has received a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (IGC-501). The formulation also received an intent to grant from the European Patent Office. With these awards, and a previous one, the formulation for treating seizures is protected in the U.S., Canada, and certain European countries.

Jun 05, 2023 08:30 am ET

IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award

IGC Pharma, Inc (NYSE American: IGC) ("IGC" or the "Company"), today announced that its Advisor, Professor T. Govindaraju the inventor of the investigational Alzheimer’s drug candidate, TGR-63, received the Government of India-instituted National Technology Award (Translational Research) for “Outstanding Contribution in Commercializing Innovative Indigenous Technologies” from the Minister of State for Science and Technology and Earth Sciences.

May 18, 2023 08:30 am ET

IGC Pharma to Present at LD Micro Invitational XIII

Presentation on Tuesday, June 6 at 3:00 PM PT

Mar 22, 2023 08:30 am ET

IGC Pharma to Attend Investor Summit

Potomac, Maryland--(Newsfile Corp. - March 22, 2023) - IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company") today announced that Ram Mukunda, Chief Executive Officer, and Claudia Grimaldi, Principle Financial Officer, will attend the Investor Summit on Wednesday, March 29, 2023. Mr. Mukunda and Ms. Grimaldi will give a virtual company presentation at 11:30 am ET and be available for virtual one-on-one meetings throughout the day.

Mar 20, 2023 08:45 am ET

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects...

Feb 14, 2023 07:41 pm ET

IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022

via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal quarter 2023 financial results. Third Fiscal Quarter 2023 Highlights: The...

Feb 08, 2023 08:30 am ET

IGC to be Featured in Feb. 10 Radius Research Investor Webinar

via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia Grimaldi, PFO, will be featured in an investor webinar hosted by Radius Research on Friday, Feb....

Jan 04, 2023 08:00 am ET

IGC Receives No Objection Letter from Health Canada

via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it has received a no objection letter from Health Canada for approval of its trial, “A Phase 2, Multi-Center, Double-Blind,...

Dec 20, 2022 08:30 am ET

IGC Announces Updated Life Sciences Presentation

India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announces that a life sciences presentation has been filed with the SEC on Form 8K and is available at https://www.sec.gov/. The presentation is also...

Dec 07, 2022 08:30 am ET

IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act

via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”), applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act (“the Act”), which was signed into law by President Biden on...

Dec 01, 2022 08:30 am ET

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease

India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease”.

Nov 30, 2022 11:19 am ET

IGC to Present at the RHK 2022 Disruptive Growth Conference

India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will be presenting at the RHK Disruptive Growth Conference in New York City on Monday, December 5 at 11:20 am...

Nov 01, 2022 04:30 pm ET

IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022

India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today reported its second fiscal quarter 2023 financial results.

Sep 21, 2022 06:00 am ET

IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease.”

Sep 12, 2022 07:00 am ET

IGC Announces Results of its 2022 Annual Stockholders Meeting

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on September 9, 2022 (the “Annual Meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 25, 2022, were passed by the requisite vote of the stockholders. Only stockholders of record on the record date of July 13, 2022 were entitled to and requested to vote at the Annual Meeting.

Aug 08, 2022 06:00 am ET

IGC Reports Financial Results for the Quarter Ended June 30, 2022

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company’s 2023 fiscal year.

Jun 22, 2022 11:26 pm ET

IGC Reports Financial Results for Fiscal Year Ended March 31, 2022

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces its financial results for Fiscal Year Ended March 31, 2022.

Jun 21, 2022 12:15 am ET

IGC Acquires Exclusive Rights for a Potential Alzheimer’s Drug Development Candidate

India Globalization Capital, Inc. (NYSE: IGC) is excited to announce that one of its subsidiaries reached an Intellectual Property (IP) license agreement for a potential Alzheimer’s drug development candidate.

Jun 08, 2022 09:03 pm ET

IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders

India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a patent (#11,351,152) to the Company titled “Method and Composition for Treating Seizure Disorders.”

Apr 18, 2022 05:28 pm ET

India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits

India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announces today that on April 13, 2022, the United States District Court for the District of Maryland entered an Order granting final approval of a settlement the Company and two of its officers (the “Class Action Defendants”) and the plaintiffs in two (2) previously disclosed shareholder class action lawsuits, both filed on November 2, 2018 and then consolidated on February 28, 2019: Tchatchou v. India Globalization Capital, Inc., et al., Civil Action No. 8:18-cv-03396; and Harris-Carr v. India Globalization Capi

Mar 23, 2022 04:55 pm ET

India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors

India Globalization Capital, Inc. (NYSE American: IGC) announces that the Board has appointed Ms. Claudia Grimaldi as a non-independent Director, effective March 23, 2022. IGC now has 5 directors including a majority who are independent.

Feb 21, 2022 08:00 am ET

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock - IGC

GREENBELT, Md., Feb. 21, 2022 /PRNewswire/ -- The Rosen Law Firm, P.A. and Pomerantz LLP announce that the United States District Court for the District of Maryland has approved the following announcement of a proposed securities class action settlement that would benefit purchasers of India Globalization Capital, Inc. common stock (NYSEAMERICAN: IGC):

Feb 14, 2022 09:00 am ET

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock – IGC

The Rosen Law Firm, P.A. and Pomerantz LLP announce that the United States District Court for the District of Maryland has approved the following announcement of a proposed securities class action settlement that would benefit purchasers of India...

Feb 10, 2022 04:30 pm ET

IGC Reports Financial Results for the December 31, 2021 Quarter

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the three months ending December 31, 2021 – quarter three of the Company’s 2022 fiscal year.

Feb 07, 2022 09:00 am ET

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock – IGC

Jan 31, 2022 08:00 am ET

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock - IGC

GREENBELT, Md., Jan. 31, 2022 /PRNewswire/ -- The Rosen Law Firm, P.A. and Pomerantz LLP announce that the United States District Court for the District of Maryland has approved the following announcement of a proposed securities class action settlement that would benefit purchasers of India Globalization Capital, Inc. common stock (NYSEAMERICAN: IGC):

Jan 24, 2022 09:00 am ET

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock – IGC

Jan 19, 2022 09:29 am ET

India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors

India Globalization Capital, Inc. (NYSE American: IGC) is excited to announce that the Board has appointed former Congressman Jim Moran (“Congressman Moran”) as an independent Director. IGC is delighted to welcome Congressman Moran to its Board of Directors.

Jan 17, 2022 09:00 am ET

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock – IGC

Dec 14, 2021 09:25 am ET

Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug

(NYSE American: IGC), India Globalization Capital, Inc. (“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease.

Dec 08, 2021 05:43 pm ET

Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer’s Patients

(NYSE American: IGC), India Globalization Capital, Inc. (IGC) today announces preliminary results for its exploratory endpoints from its Phase 1 IGC-AD1 clinical trial. IGC-AD1 is a proprietary cannabis-based investigational new drug candidate for patients suffering from Alzheimer’s disease. The Phase 1 clinical trial provided valuable insights on Pharmacokinetics (PK) and genotyping that will be essential in determining optimal dosing moving into subsequent trials, subject to U.S. Food and Drug Administration (FDA) approval.

Dec 02, 2021 09:32 am ET

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

(NYSE American: IGC), India Globalization Capital, Inc. (IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The investigational new drug, IGC-AD1, is IGC’s proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimer’s disease. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Oct 29, 2021 10:09 pm ET

IGC Reports Financial Results for the September 30, 2021 Quarter

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year.

Oct 15, 2021 04:00 pm ET

IGC Announces Results of its 2021 Annual Stockholders Meeting

India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces that during its Annual Meeting of Shareholders scheduled for and convened on October 15, 2021, voting on all matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on September 15, 2021, were passed. Only stockholders of record on the record date of September 10, 2021, were entitled to and were being requested to vote.

Sep 07, 2021 07:30 pm ET

IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability

(NYSE American: IGC), India Globalization Capital, Inc. (“IGC”, or the “Company”), today announces the completion of its Phase 1 clinical trial on IGC’s cannabis-based investigational new drug, IGC-AD1, for patients suffering from Alzheimer’s disease. As previously disclosed, IGC submitted IGC-AD1 to the U.S. Food and Drug Administration (“FDA”) under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the Phase 1 trial from the FDA on July 30, 2020.

Aug 11, 2021 08:00 pm ET

IGC Reports Financial Results for the June 30, 2021, Quarter

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the three months ended June 30, 2021.

Jul 22, 2021 07:00 am ET

IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC

India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announced today that on July 20, 2021, the United States Patent and Trademark Office (“USPTO”) issued a patent (#11,065,225) for the treatment of Alzheimer’s disease entitled “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease.”

Jun 23, 2021 06:50 pm ET

IGC Completes the Final Cohort of Its Phase 1 Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces today it has completed Cohort 3 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. As previously disclosed, IGC submitted IGC-AD1, its investigational drug candidate for Alzheimer’s, to the U.S. Food and Drug Administration (“FDA”) under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the Phase 1 trial, on Alzheime

Jun 14, 2021 06:00 pm ET

IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the Fiscal Year Ended March 31, 2021.

Jun 07, 2021 11:26 pm ET

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. (“IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. As previously disclosed, IGC submitted IGC-AD1 to the U.S. Food and Drug Administration (“FDA”) under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the trial from the FDA on July 30, 2020.

May 14, 2021 06:01 am ET

India Globalization Capital (IGC) Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces today that it has completed Cohort 1 of its Phase 1 clinical trial testing the IGC’s tetrahydrocannabinol (“THC”)-based formulation, IGC-AD1, intended to alleviate the symptoms of participants suffering from Alzheimer’s disease. As previously disclosed, IGC’s Investigational New Drug, IGC-AD1, a THC-based formulation, was submitted to the U.S. Food and Drug Administration (“FDA”) under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the trial from the FDA

Mar 08, 2021 06:33 pm ET

IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain

India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announced today that on March 2, 2021, the Company received one more patent (patent#10,933,082) from the United States Patent and Trademark Office (“USPTO”) for the Company’s cannabinoid composition and method for treating pain in patients with Psoriatic Arthritis, Fibromyalgia, Scleroderma and other conditions. The patent application was filed on October 1, 2018. The latest patent approval adds to the Company’s existing patent portfolio, which includes patent issuances by the USPTO for seizure disorders and eating disorder

Feb 22, 2021 08:00 am ET

Update On IGC’s Phase 1 Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) is pleased to announce the progress of its tetrahydrocannabinol (THC)-based phase 1 clinical trial, which was approved to proceed by the U.S. Food and Drug Administration (“FDA”) on July 30, 2020, as previously disclosed.

Feb 12, 2021 07:00 pm ET

IGC Reports Financial Results for December 31, 2020 Quarter

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended December 31, 2020, which is the third quarter of its 2021 fiscal year.

Jan 13, 2021 06:19 pm ET

IGC Announces Results of its 2020 Annual Stockholders Meeting

India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces that during its Annual Meeting of Shareholders scheduled for, and convened on January 11, 2021, voting on all matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on December 8, 2020 were passed. Only stockholders of record on the record date of November 20, 2020, were entitled to and were being requested to vote.

Dec 22, 2020 08:00 am ET

India Globalization Capital Nominates Mr. John E. Lynch to its Board of Directors

India Globalization Capital, Inc. (NYSE American: IGC), today announced that John E. Lynch has been nominated as a Class A independent director for election at the Company’s 2020 Annual Meeting of Stockholders, to be held on January 11, 2021, replacing Class A director Sudhakar Shenoy.

Nov 23, 2020 09:00 am ET

IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’s Patients

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announced that it is enrolling participants suffering from mild to severe dementia due to Alzheimer’s disease for its Phase 1 clinical trial.

Nov 22, 2020 08:48 pm ET

IGC Reports Financial Results for September 30, 2020 Quarter and Start of Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients

India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended September 30, 2020, which is the second quarter of its 2021 fiscal year, and the start of Phase 1 cannabinoid-based clinical trial for Alzheimer’s Patients.

Aug 20, 2020 02:45 pm ET

CORRECTING and REPLACING IGC Reports Financial Results for June 30, 2020 Quarter and Prepares for Phase 1 Cannabinoid Clinical Trial for Alzheimer’s Patients

Please replace the release dated August 19, 2020 with the following corrected version due to multiple revisions.

Aug 19, 2020 04:18 pm ET

IGC Reports Financial Results for the Quarter Ended June 30, 2020 While Preparing for Its FDA-Approved Cannabinoid Clinical Trials on Alzheimer’s Patients

India Globalization Capital, Inc. (NYSE American: IGC) today announced financial results for the quarter ended June 30, 2020, which is the first quarter of its 2021 fiscal year.

Aug 11, 2020 05:03 pm ET

FDA Approves Initiation of IGC’s Cannabinoid Trial on Alzheimer’s Patients

India Globalization Capital (“IGC” or the “Company”) (NYSE American: IGC) announced today that on July 30, 2020, the U.S. Food and Drug Administration (FDA) notified IGC that it has authorized the Company to initiate a Phase 1 human trial study for the Company’s investigational cannabinoid formulation for the treatment of patients suffering from mild to severe dementia due to Alzheimer’s disease. After the completion of administrative tasks, the Company plans to begin enrolling patients suffering from Alzheimer’s-related dementia for a 12-subject safety Multiple Ascending Dose (MAD) Study. The

Jul 21, 2020 07:00 am ET

IGC Filed a Patent Application with the U.S. Patent Office for a New Formulation to Treat Pain

On July 17, 2020 India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) filed a patent application, IGC-511, with the United States Patent and Trademark Office (“USPTO”) for a new cannabinoid formulation intended for the treatment of chronic pain, muscular pain, and neuropathic pain in humans and veterinary animals.

Jul 20, 2020 07:00 am ET

IGC Receives a Notice of Allowance from the U.S. Patent Office

India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) recently received a Notice of Allowance dated July 8, 2020 from the United States Patent and Trademark Office (“USPTO”) for the Company’s cannabinoid formulation for the treatment of seizures in humans and veterinary animals. IGC filed this application for its IGC-502 formulation and method (#15/104,556) on June 15, 2016. The USPTO issues a Notice of Allowance if, after examination by a patent examiner, it appears that the applicant is entitled to a patent under the law. The actual issuance of the patent could take several

Jul 13, 2020 04:45 pm ET

IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the Fiscal Year Ended March 31, 2020.

May 07, 2020 10:00 pm ET

India Globalization Capital, Inc. Announces Proposed Settlement of Three Derivative Lawsuits and Provides Notice to Shareholders

India Globalization Capital, Inc. (the “Company”) (NYSE: IGC) announces today the proposed settlement of three derivative lawsuits pending since 2018 and 2019 and provides notice to shareholders of the settlement.

Mar 26, 2020 08:30 pm ET

IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

India Globalization Capital, Inc. (the “Company”) (NYSE: IGC) recently received notification that on March 24, 2020, the United States Patent and Trademark Office (“USPTO”) issued a method and composition patent (#10,596,159 B2) for the Company’s cannabinoid formulation for the treatment of cachexia and eating disorders in humans and veterinary animals. IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016. A public copy of the patent is available on the USPTO website.

Feb 10, 2020 05:30 pm ET

IGC Reports Financial Results for the Quarter Ended December 31, 2019

India Globalization Capital, Inc. (NYSE American: IGC) today announced financial results for the quarter ended December 31, 2019, which is the third quarter of its 2020 fiscal year.

Nov 06, 2019 07:00 am ET

IGC Reports Financial Results for the Quarter Ended September 30, 2019

India Globalization Capital, Inc. (NYSE American: IGC) today announced financial results for the quarter ended September 30, 2019, which is the second quarter of its 2020 fiscal year.

Oct 04, 2019 07:00 am ET

IGC Opens Marketing and Research Hub in Colombia

India Globalization Capital, Inc. (NYSE: IGC) announced today that it has opened a marketing and research office in Colombia, South America. Hamsa Biochem SAS, a new beneficially owned subsidiary of IGC, will focus on marketing and research initiatives to advance Hyalolex™, Holi Hemp™, and other products in Latin America and among the greater Hispanic community in the United States, in compliance with applicable law and regulations. Hyalolex™, which is currently available in more than 40 dispensaries in Puerto Rico, is based on a formulation described in a patent filing acquired from the Unive

Sep 19, 2019 07:00 am ET

IGC Announces IRB Approval of its IGC-AD1 for a Phase-2 study

India Globalization Capital, Inc. (NYSE: IGC) announced today that the Institutional Review Board (“IRB”), in Puerto Rico, approved its protocol for a double-blind, placebo-controlled, efficacy, safety and tolerability study of its proprietary formulation IGC-AD1 on behavior and functionality in subjects with dementia from Alzheimer’s disease.

Aug 09, 2019 07:00 am ET

IGC Reports Financial Results for the Quarter Ended June 30, 2019

India Globalization Capital, Inc. (NYSE American: IGC) today announced its financial results for the quarter ended June 30, 2019, which is the first quarter of its 2020 fiscal year.

Jul 26, 2019 05:25 pm ET

Lifshitz & Miller LLP Announces Investigation of Amneal Pharmaceuticals, Inc., CareDx, Inc., Casa Systems, Inc., India Globalization Capital, Inc., Just Energy Group Inc., LegacyTexas Financial Group,

NEW YORK, July 26, 2019 /PRNewswire/ --

Jun 17, 2019 07:00 am ET

IGC Reports Financial Results for the Fiscal Year Ended March 31, 2019

India Globalization Capital, Inc. (NYSEAM: IGC) announces its financial results for the Fiscal Year Ended March 31, 2019.

Jun 13, 2019 05:32 pm ET

IGC to Participate in Arizona’s Industrial Hemp Program

India Globalization Capital, Inc. (NYSE: IGC) announces that its subsidiary Holi Hemp’s application has been approved and that it has executed agreements with operators to grow and harvest industrial hemp under the terms and conditions of the Industrial Hemp Program developed by the Arizona Department of Agriculture (AZDA).

Jun 12, 2019 05:40 pm ET

Robbins Arroyo LLP: India Globalization Capital, Inc. (IGC) Sued for Misleading Investors

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of India Globalization Capital, Inc. (AMEX: IGC) has filed a derivative complaint against the company's officers and directors for breaches of fiduciary duty from October 25, 2017 through the present. India Globalizati

Apr 22, 2019 07:00 am ET

IGC Announces Continued Educational Initiatives in Support of Hyalolex

India Globalization Capital, Inc. (NYSE: IGC) announces that it will host educational conferences in two of the largest cities in Puerto Rico on April 27, 2019 (San Juan) and April 28, 2019 (Ponce) from 9:00 a.m. to 5:00 p.m. each day. These full-day events will feature presentations for physicians in the morning and provide programs tailored to technicians, patients, and caregivers in the afternoon. These events are part of a series of educational initiatives IGC is hosting in support of Hyalolex™, the Company’s cannabinoid-based product design

Mar 26, 2019 09:00 pm ET

IGC Provides Corporate Updates

India Globalization Capital, Inc. (NYSE:IGC) announces today that, as of Wednesday, March 27, 2019, Hyalolex™, the Company’s cannabinoid-based, non-FDA approved product designed to assist in helping improve the lives of patients suffering from Alzheimer’s disease, will be available for purchase in select dispensaries in San Juan, Puerto Rico. The MSRP for a 30 ml bottle of Hyalolex™ is $55.00. For more information about Hyalolex™, visit the Company’s recently updated website at

Feb 21, 2019 07:52 pm ET

IGC Announces Successful Appeal of Delisting Proceedings and Imminent Relisting on NYSE American

India Globalization Capital, Inc. (NYSE American: IGC; PINK: IGCC) announced today that it has successfully challenged NYSE American’s decision to delist the common stock of the Company from trading on the Exchange under the Exchange’s appeal procedures.

Jan 02, 2019 10:00 am ET

FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against India Globalization Capital, Inc. (IGC) & Lead Plaintiff Deadline - January 2, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against India Globalization Capital, Inc. ("India Globalization" or the "Company") (NYSE: IGC) and certain of its officers, on...

Jan 01, 2019 12:01 pm ET

WEDNESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact t

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against India Globalization Capital, Inc. (“India Globalization” or “the Company”) (NYSE: IGC, OTC: IGCC) for violations of §§10(b)...

Dec 31, 2018 01:36 pm ET

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of India Globalization Capital, Inc. (“India Globalization” or “the Company”) (NYSE:

Dec 31, 2018 10:00 am ET

FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against India Globalization Capital, Inc. (IGC) & Lead Plaintiff Deadline - January 2, 2019

Dec 30, 2018 10:14 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in India Globalization Capital, Inc. of Class Action Lawsuit and Upcoming Deadline – IGC; IGCC

Pomerantz LLP announces that a class action lawsuit has been filed against India Globalization Capital, Inc. (“India Globalization” or the “Company”) (NYSE: IGC)(OTCMKTS: IGCC) and certain of its officers. The class action, filed in United States...

Dec 28, 2018 01:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fitbit, India Globalization, and Aphria and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Fitbit, Inc., India Globalization Capital, Inc., and Aphria Inc. Stockholders have until the deadlines listed below to...

Dec 24, 2018 10:40 am ET

EARLY JANUARY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to

Dec 24, 2018 10:00 am ET

DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against India Globalization Capital, Inc. (IGC) & Lead Plaintiff Deadline - January 2, 2019

Dec 23, 2018 12:00 am ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, Fitbit, India Globalization, and Aphria and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Bank OZK, Fitbit, Inc., India Globalization Capital, Inc., and Aphria Inc. Stockholders have until the deadlines listed below...

Dec 21, 2018 05:47 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in India Globalization Capital, Inc. of Class Action Lawsuit and Upcoming Deadline - IGC; IGCC

NEW YORK, Dec. 21, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against India Globalization Capital, Inc. ("India Globalization" or the "Company") (NYSE: IGC)(OTCMKTS: IGCC) and certain of its officers. The class action, filed in United States District Court, District of Maryland, and index under 18-cv-03408, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise, acquired India Globalization securities between June 21, 2018 through October 29, 2018, both dates inclusi

Dec 20, 2018 03:44 pm ET

DEADLINE ALERT: Rosen Law Firm Reminds India Globalization Capital, Inc. Investors of Important Deadline in First Class Action Filed by Firm – IGC, IGCC

Dec 19, 2018 10:00 am ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against India Globalization Capital, Inc. (IGC) & Lead Plaintiff Deadline: January 2, 2019

Dec 18, 2018 08:20 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, Fitbit, India Globalization, and Aphria and Encourages Investors to Contact the Firm

Dec 17, 2018 02:15 pm ET

UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to C

Dec 14, 2018 05:23 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in India Globalization Capital, Inc. of Class Action Lawsuit and Upcoming Deadline – IGC; IGCC

Dec 13, 2018 05:54 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In India Globalization Capital, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in India Globalization Capital, Inc. (“India Globalization” or the “Company”) (formerly, NYSE:IGC) (Other OTC:IGCC) of the January 2, 2019 deadline to seek the role of...

Dec 12, 2018 07:48 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, India Globalization, Align Technology, and Aphria and Encourages Investors to Contact the Fir

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Bank OZK, India Globalization Capital, Inc., Align Technology, Inc., and Aphria Inc. Stockholders have until the deadlines...

Dec 12, 2018 11:25 am ET

IGCC NOTICE: Rosen Law Firm Announces First Securities Class Action Lawsuit Against India Globalization Capital, Inc.; Important Deadline - IGC, IGCC

NEW YORK, Dec. 12, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of India Globalization Capital, Inc. (NYSE: IGC, OTC: IGCC) from October 25, 2017 through October 29, 2018, inclusive (the "Class Period"). The lawsuit seeks to recover damages for India Globalization investors under the federal securities laws.

Dec 11, 2018 07:47 pm ET

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of India Globalization Capital, Inc. Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased India Globalization Capital, Inc. (“India Globalization” or the “Company”) (OTC: IGC,

Dec 10, 2018 05:30 pm ET

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to Cont

Dec 10, 2018 10:00 am ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against India Globalization Capital, Inc. (IGC) & Lead Plaintiff Deadline: January 2, 2019

Dec 07, 2018 08:00 pm ET

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against India Globalization Capital, Inc. and Encourages Investors to Contact the Firm Before January 2

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all persons or entities who acquired India Globalization Capital, Inc. (“India Globalization” or the “Company”) (NYSE:

Dec 07, 2018 04:38 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in India Globalization Capital, Inc. of Class Action Lawsuit and Upcoming Deadline – IGC; IGCC

Dec 07, 2018 11:39 am ET

CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In India Globalization Capital, Inc. (NYSE: IGC) (Other OTC

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of purchasers of India Globalization...

Dec 06, 2018 08:17 pm ET

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of India Globalization Capital, Inc. Investors (IGCC)

Glancy Prongay & Murray LLP (“GPM”), a global investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired India Globalization Capital, Inc. (“India Globalization” or the “Company”) (OTC:

Dec 06, 2018 10:00 am ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against India Globalization Capital, Inc. (IGC) & Lead Plaintiff Deadline: January 2, 2019

Dec 04, 2018 05:31 pm ET

IGCC NOTICE: Rosen Law Firm Reminds India Globalization Capital, Inc. Investors of Important Deadline First Class Action Filed by Firm– IGC, IGCC

Dec 03, 2018 03:48 pm ET

INVESTOR NOTICE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contac

Dec 03, 2018 10:00 am ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against India Globalization Capital, Inc. (IGC, IGCC) and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been filed in the U.S. District Courts for the Eastern District of New York and the District of Maryland on behalf of all persons or entities who purchased or otherwise...

Nov 30, 2018 05:16 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in India Globalization Capital, Inc. of Class Action Lawsuit and Upcoming Deadline – IGC; IGCC

Nov 27, 2018 08:34 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bank OZK, India Globalization, and Align Technology and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Bank OZK, India Globalization Capital, Inc., and Align Technology, Inc. Stockholders have until the deadlines listed below to...

Nov 27, 2018 06:23 pm ET

IGCC ALERT NOTICE: Rosen Law Firm Reminds India Globalization Capital, Inc. Investors of Important Deadline in First Class Action Filed by Firm – IGC, IGCC

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of India Globalization Capital, Inc. (NYSE: IGC, OTC: IGCC) from October 25, 2017 through October 29, 2018, inclusive (the “Class Period”) of the December 31, 2018 lead plaintiff deadline in the first filed class action commenced by the Rosen Firm. The lawsuit seeks to recover damages for India Globalization investors under the federal securities laws.

Nov 27, 2018 02:52 pm ET

CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In India Globalization Capital, Inc. (NYSE: IGC) (Other OTC

Nov 27, 2018 11:27 am ET

January 2nd IGC Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against India Globalization Capital, Inc. – IGC, IGCC

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important January 2, 2019 lead plaintiff deadline in the shareholder class action lawsuit against India Globalization Capital, Inc. (“IGC” or the...

Nov 27, 2018 10:00 am ET

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against India Globalization Capital, Inc. (IGC) & Lead Plaintiff Deadline: January 2, 2019

Nov 26, 2018 01:05 pm ET

INVESTOR ALERT NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contac

Nov 23, 2018 06:19 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in India Globalization Capital, Inc. of Class Action Lawsuit and Upcoming Deadline – IGC; IGCC

Nov 20, 2018 02:52 pm ET

CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In India Globalization Capital, Inc. (NYSE: IGC) (Other OTC

Nov 20, 2018 01:14 pm ET

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to Conta

Nov 20, 2018 11:16 am ET

Lifshitz & Miller LLP Announces Investigation of Cognizant Technology Solutions Corp., Costco Wholesale Corporation, Datawatch Corporation, Dycom Industries, Inc., India Globalization Capital, Inc., M

NEW YORK, Nov. 20, 2018 /PRNewswire/ --

Nov 16, 2018 04:58 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in India Globalization Capital, Inc. of Class Action Lawsuit and Upcoming Deadline – IGC; IGCC

Nov 15, 2018 02:12 pm ET

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contac

Nov 12, 2018 07:59 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fitbit, India Globalization, and Apogee and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Fitbit, Inc., India Globalization Capital, Inc., and Apogee Enterprises, Inc. Stockholders have until the deadlines listed...

Nov 11, 2018 10:15 am ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ADNT, GOOG, IGC and ALGN

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Nov 10, 2018 08:42 am ET

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to

Nov 09, 2018 03:46 pm ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In India Globalization Capital, Inc. To Contact The Firm

Nov 09, 2018 01:18 pm ET

SHAREHOLDER ALERT: TGTX CPB CHGG ADNT GOOG IGC ALGN SYF RYAAY AQUA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...

Nov 08, 2018 05:28 pm ET

CLASS ACTION UPDATE for IGC, ALGN and AQUA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...

Nov 08, 2018 01:00 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRCO, CPB, DY, IGC and FIT

Nov 08, 2018 11:23 am ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In India Globalization Capital, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in India Globalization Capital, Inc. (“India Globalization” or the “Company”) (NYSE:IGC) (Other OTC:IGC) of the January 2, 2019 deadline to seek the role of lead...

Nov 07, 2018 12:29 pm ET

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, COST, HTHT, IGC, ALGN and SYF

Nov 07, 2018 10:29 am ET

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In India Globalization Capital, Inc. To Contact The Firm

NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in India Globalization Capital, Inc. ("India Globalization" or the "Company") (formerly, NYSE:IGC) (Other OTC:IGC) of the January 2, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Nov 06, 2018 04:12 pm ET

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to

Nov 06, 2018 03:59 pm ET

SHAREHOLDER ALERT: OPK APOG ALNY MGTI CPB CHGG DY IGC FIT SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

Nov 06, 2018 03:25 pm ET

IGCC LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit Against India Globalization Capital, Inc.; Important Deadline – IGC, IGCC

Nov 05, 2018 08:47 pm ET

INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against India Globalization Capital, Inc.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who purchased or acquired India Globalization Capital, Inc. (“India Globalization” or the “Company”) (NYSE:

Nov 05, 2018 07:00 pm ET

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against India Globalization Capital, Inc. (IGC) (IGCC)

Gainey McKenna & Egleston announces that a class action lawsuit has been filed against India Globalization Capital, Inc. (“India Globalization” or the “Company”) (NYSE: IGC, OTC: IGCC) in the United States District Court for the Eastern District of...

Nov 05, 2018 06:51 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Alnylam, Acadia, and India Globalization and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Alnylam Pharmaceuticals, Inc., Acadia Healthcare Company, Inc., and India Globalization Capital, Inc. Stockholders have until...

Nov 05, 2018 04:50 pm ET

CLASS ACTION UPDATE for IGC and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Nov 05, 2018 04:42 pm ET

INDIA GLOBALIZATION INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In India Globalization Capital, Inc. To Contact The Firm

NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against India Globalization Capital, Inc. ("India Globalization" or the "Company") (formerly, NYSE:IGC) (Other OTC:IGC).

Nov 05, 2018 01:20 pm ET

Pomerantz Law Firm Announces the Filing of a Class Action against India Globalization Capital, Inc. and Certain Officers – IGC

Pomerantz LLP announces that a class action lawsuit has been filed against India Globalization Capital, Inc. (“India Globalization” or the “Company”) (NYSE: IGC) and certain of its officers. The class action, filed in United States District...

Nov 05, 2018 12:41 pm ET

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $500,000 to Con

Nov 05, 2018 07:00 am ET

IGC Class Action Lawsuit: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against India Globalization Capital, Inc. – IGC, IGCC

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of India Globalization Capital, Inc. (“IGC” or the...

Nov 03, 2018 06:35 pm ET

IGC Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against India Globalization Capital, Inc. -- IGC, IGCC

NEW YORK, Nov. 3, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of India Globalization Capital, Inc. ("IGC" or the "Company") (NYSE: IGC) (OTC: IGCC) between October 25, 2017 and October 29, 2018, both dates inclusive (the "Class Period"). The lawsuit seeks to recover IGC shareholders' investment losses.

Nov 02, 2018 05:31 pm ET

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against India Globalization Capital, Inc. (IGC, IGCC) and Encourages India Globalization Investors to Contact the Firm

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired India Globalization Capital,...

Nov 02, 2018 04:16 pm ET

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against India Globalization Capital, Inc. – IGC, IGCC

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of India Globalization Capital, Inc. (NYSE: IGC, OTC: IGCC) from October 25, 2017 through October 29, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for India Globalization investors under the federal securities laws.

Nov 01, 2018 12:18 pm ET

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the

Oct 31, 2018 01:32 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against India Globalization Capital, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Oct 31, 2018 10:00 am ET

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of India Globalization Capital, Inc. (IGC)

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of India Globalization Capital, Inc. ("India Globalization" or the "Company") (NYSE: IGC). Such investors are encouraged to obtain...

Oct 30, 2018 06:44 pm ET

Bragar Eagel & Squire, P.C. is Investigating India Globalization Capital, Inc. (IGC) on Behalf of Stockholders and Encourages IGC Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against India Globalization Capital, Inc. (NYSE: IGC). Our investigation concerns whether India Globalization has violated the federal securities laws and/or engaged in other unlawful...

Oct 30, 2018 04:45 pm ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of India Globalization Capital, Inc.

Levi & Korsinsky announces it has commenced an investigation of India Globalization Capital, Inc. (“India Globalization” or “the Company”) (NYSE American: IGC) concerning possible violations of federal securities laws. On October 29, 2018 India...

Oct 30, 2018 04:33 pm ET

IGC LOSSES ALERT: Bernstein Liebhard LLP Announces First Investigation of India Globalization Capital, Inc. - IGC

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of India Globalization Capital, Inc. (“India Globalization” or the “Company”) (NYSE: IGC) (OTC:...

Oct 30, 2018 04:00 pm ET

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against India Globalization Capital, Inc. – IGC

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of India Globalization Capital, Inc. (NYSE:IGC) resulting from allegations that India Globalization may have issued materially misleading business information to the investing public.

Oct 30, 2018 11:17 am ET

IGC Losses Alert: Bernstein Liebhard LLP Announces Investigation Of India Globalization Capital, Inc. - IGC

NEW YORK, Oct. 30, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of India Globalization Capital, Inc. ("India Globalization" or the "Company") (NYSE: IGC) resulting from allegations that India Globalization and/or its executives may have issued materially misleading business information to the investing public.

Oct 30, 2018 07:00 am ET

IGC to Re-list Securities on Alternative Exchange

India Globalization Capital, Inc. (NYSE American: IGC) announces today that it is in the process of evaluating applications with alternative exchanges in the U.S. and Canada to list its common stock for public trading. IGC is working diligently to complete this process as quickly as possible and will provide additional updates in the very near term. Liquidity, elimination of unfair restrictions with respect to the commercialization of products, and customized support are expected to be key selection points.

Oct 29, 2018 06:40 pm ET

NYSE American to Suspend Trading in India Globalization Capital and Commence Delisting Proceedings

India Globalization Capital, Inc. (NYSE American: IGC) announces today that it received a letter from the staff of NYSE Regulation informing the Company that it has determined to commence proceedings to delist the common stock of India Globalization Capital, Inc. from the Exchange. Trading in the Company’s common stock on the NYSE American will be suspended immediately.

Oct 16, 2018 08:00 am ET

IGC Announces Financial Results for Quarter Ended September 30, 2018

India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces financial results for the quarter ended September 30, 2018, which is the second quarter of its 2019 fiscal year.

Oct 09, 2018 06:09 pm ET

IGC Files Provisional Patent to Protect IP for CBD-Infused Energy Drink

India Globalization Capital, Inc. (NYSE AMERICAN: IGC) today announced that it has filed a provisional method and composition patent application (IGC-509) with the U.S. Patent and Trademark Office (USPTO) for the treatment of fatigue and energy restoration. The filing is for a provisional patent and no assurance can be given as to whether or when a registered patent may be granted by the USPTO in the future.

Oct 03, 2018 09:31 am ET

Thinking about buying stock in DavidsTea, India Globalization Capital, Oragenics Inc, Stitch Fix or vTv Therapeutics?

NEW YORK, Oct. 3, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DTEA, IGC, OGEN, SFIX, and VTVT.

Oct 02, 2018 08:40 pm ET

IGC Completes At-The-Market Offerings

India Globalization Capital, Inc. (NYSE AMERICAN:IGC) announced today that it completed its at-the-market equity offering programs described in its prospectus supplements dated September 24, 2018 and October 1, 2018 and filed with the SEC. The programs commenced on September 25, 2018 and were completed on October 2, 2018. In total, 5,654,375 shares of common stock were sold at a weighted average stock price of approximately $5.30, representing gross proceeds of approximately $30.0 million. Following the completion of the programs, IGC has approx

Sep 25, 2018 08:39 pm ET

IGC to Enter the Hemp/CBD-Infused Energy Drink Space

India Globalization Capital, Inc. (NYSE AMERICAN: IGC) announces today that it has executed a distribution and partnership agreement for several products including a sugar free, energy drink called ‘Nitro G’.

Sep 24, 2018 09:31 am ET

Thinking about buying stock in Apple, Comcast, India Globalization Capital, New Age Beverages Corp or Sirius XM Holdings?

NEW YORK, Sept. 24, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CMCSA, IGC, NBEV, and SIRI.

Sep 13, 2018 09:00 am ET

U.S. Medical Cannabis Market Set to Expand as Legalization Rapidly Spreads

NEW YORK, September 13, 2018 /PRNewswire/ --

Sep 13, 2018 07:00 am ET

India Globalization Capital Raises $1 Million in Direct Equity Investment to Support Hyalolex Commercialization

India Globalization Capital, Inc. (NYSE American: IGC), a company engaged in the development and commercialization of cannabinoid-based alternative therapies for medical conditions including Alzheimer’s disease, Parkinson’s disease, and pain, announced that it raised $1.0 million in a private placement of restricted shares.

Aug 14, 2018 07:00 am ET

IGC to Enter California Market with Hyalolex

India Globalization Capital, Inc. (NYSE American:IGC) announces that it has designated California as a priority market for Hyalolex, its lead cannabis-based supplement for treating and managing Alzheimer’s patients.

Aug 06, 2018 09:00 pm ET

IGC Announces Results of its 2018 Annual Stockholders Meeting

India Globalization Capital, Inc. (NYSE American: IGC) announces that during its Annual Meeting of Shareholders scheduled for, and convened on August 6, 2018, voting on all matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on July 6, 2018 were passed. Only stockholders of record on the record date of July 5, 2018 were entitled to and were being requested to vote. At the Annual Meeting, the following proposals were approved: (i) the election of Richard Prins to the Company’s board of directors, (ii) the proposal to ratif

Aug 02, 2018 07:00 pm ET

IGC Announces Financial Results for Quarter Ended June 30, 2018

India Globalization Capital, Inc. (NYSE AMERICAN: IGC) today announces financial results for the quarter ended June 30, 2018, which is the first quarter of its 2019 fiscal year.

Jul 25, 2018 08:00 am ET

IGC Announces “Drops of Clarity” Marketing Initiatives for Hyalolex™

India Globalization Capital, Inc. (NYSE American:IGC) announces the launch of its branding campaign and marketing outreach for Hyalolex™, an oral cannabinoid-based supplement for the treatment of symptoms associated with Alzheimer’s.

Jul 10, 2018 07:00 am ET

IGC Annual Meeting of Stockholders: August 6, 2018

India Globalization Capital, Inc. (NYSE American: IGC) announces that it will hold its Annual Meeting of Stockholders on August 6, 2018 at 11410 Isaac Newton Sq., Suite 100, Reston, VA 20190, at 11:00 a.m. local time, for shareholders as of the record date July 5, 2018. The Annual Meeting will commence with a discussion and voting on the matters as disclosed on the Definitive Proxy on Form 14A filed with the SEC on July 6, 2018 followed by a report on our operations and strategy for growth.

Jun 21, 2018 05:38 pm ET

IGC Announces Financial Results for Fiscal Year Ended March 31, 2018

India Globalization Capital, Inc. (NYSE American:IGC) announces financial results for the fiscal year ended March 31, 2018. “In fiscal 2018, the Company’s focus was to develop, manufacture, and lay the foundation to commercialize our lead product...

May 01, 2018 09:48 am ET

India Globalization Capital: The Best of Both Worlds Approach -- CFN Media

SEATTLE, WA, May 01, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering India Globalization Capital Inc.'s (NYSE MKT: IGC)...

Apr 10, 2018 07:00 am ET

India Globalization Capital Files Patent for Hyalolex Formulation

India Globalization Capital, Inc. (NYSE Amex:IGC) today announced that it has filed a method and composition patent with the U.S.P.T.O. for the formulation of Hyalolex (IGC-507), which helps address some symptoms of Alzheimer’s disease including the buildup of plaques and tangles, anxiety, aggression and sleep disorders among others.

Mar 29, 2018 08:30 am ET

India Globalization Capital (IGC) Launches Hyalolex for Alzheimer’s -- CFN Media

SEATTLE, March 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering India Globalization Capital Inc.'s (NYSE American:IGC)...

Mar 26, 2018 09:44 am ET

Puerto Rican Alzheimer’s Patients to Be First in U.S. to Obtain Cannabis-Based Relief

BETHESDA, Md. and SAN JUAN, Puerto Rico, March 26, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) – Alzheimer’s patients in Puerto Rico will be the first in the United States to obtain Hyalolex, IGC’s proprietary...

Mar 14, 2018 09:00 am ET

IGC Partners to Advance Cannabinoid Based Parkinson's Disease Therapy Research -- CFN Media

Seattle, WA , March 14, 2018 (GLOBE NEWSWIRE) -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering India Globalization Capital Inc.’s (NYSE: American: IGC) partnership strategies that...

Mar 12, 2018 08:00 am ET

India Globalization Capital Appoints Carrolee Barlow, MD, PhD as Advisor to Help Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)

BETHESDA, Md., March 12, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) today announces that Carrolee Barlow, MD, PhD has been appointed to the Company as an Advisor to help develop solutions and treatments for Parkinson’s...

Mar 01, 2018 08:00 am ET

India Globalization Capital Partners with Parkinson’s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (

BETHESDA, Md., March 01, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) today announces that it has signed a Joint Development and Services Agreement with the prestigious Parkinson’s Institute and Clinical Center of Sunnyvale, California.

Feb 26, 2018 08:30 am ET

India Globalization Advances Pre-Clinical Studies & CAM Products -- CFN Media

Seattle Washington, Feb. 26, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering India Globalization Capital Inc’s (NYSE MKT: IGC) pursuit...

Feb 20, 2018 09:14 am ET

IGC Announces Third Quarter Financial Results Advances Hyalolex to Commercialization Stage

BETHESDA, Md., Feb. 20, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE:IGC) announced financial results for the third quarter ended December 31, 2017 for the fiscal year that ends March 31, 2018 (the “FYE2018 Q3”).

Feb 12, 2018 08:00 am ET

India Globalization Capital’s CEO to Speak at CEO Healthcare Symposium in NY on February 12 & 13

BETHESDA, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) --

Feb 08, 2018 08:30 am ET

India Globalization's Hyalolex Shows Promise in Treating Patients with Alzheimer's Disease -- CFN Media

Seattle, WA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering India Globalization Capital Inc’s (NYSE American: IGC) Hyalolex, a cannabinoid-based therapy...

Feb 08, 2018 07:30 am ET

Ram Mukunda, CEO of India Globalization Capital, Inc., Joins Everett Jolly on Uptick Newswire’s “Stock Day” Podcast

PHOENIX, Feb. 08, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) (the “Company”) provides IGC operations update on Stock Day Podcast with Everett Jolly.

Feb 01, 2018 08:30 am ET

NetworkNewsWire Announces Publication on Blockchain Disrupting New Industry Applications and Verticals

NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring India Globalization Capital (NYSE:IGC), a client of NNW engaged in...

Jan 29, 2018 09:00 am ET

India Globalization: Exciting Outlook for 2018 with Near-term Clinical Trials & Long-term Blockchain Tech -- CFN Media

SEATTLE, WA, Jan. 29, 2018 (GLOBE NEWSWIRE) -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering India Globalization Capital Inc.(NYSE: IGC) and its shift into the...

Jan 22, 2018 12:50 pm ET

India Globalization Capital Inc. Engages CFN Media to Develop New Investor Audience

SEATTLE, WA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that India Globalization Capital Inc. (NYSE: IGC) has engaged...

Jan 02, 2018 08:00 am ET

India Globalization Capital Reports Promising Spatial Memory Results in Alzheimer’s Study

BETHESDA, Md., Jan. 02, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides compelling in vivo data compiled from genetically engineered mice to mimic Alzheimer’s shows marked improvement in spatial memory.

Dec 26, 2017 08:00 am ET

India Globalization Capital to use Blockchain to Address Issues Specific to the Medical Cannabis Industry

BETHESDA, Md., Dec. 26, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), today announces that it will leverage its existing team of technology and healthcare experts to develop methods utilizing blockchain in areas such as product...

You are here

IGC Pharma Inc (A:IGC)

Business Focus: Biotechnology & Medical Research